Company Performance Metrics
BioMAS Ltd., Is an Israeli phase II clinical company, the only company worldwide to focus on the invention, development and commercialization of Tellurium-based compounds. The company’s lead molecules AS101 and SAS, are small Tellurium- based compounds developed for the treatment of various conditions with a unique integrin inhibitory property.
The molecules developed by BioMAS have Integrin inhibitory properties. Integrins are emerging therapeutic targets in many human pathologies. The ability to efficiently control their activation/deactivation has become a central focus of therapy. The novel APIs AS101/SAS have shown preclinical and clinical safety and efficacy in the following indications: (1) Autoimmune-Inflammatory diseases (like Psoriasis, Arthritis, Crohn’s and MS) (2) Certain viral conditions (like HPV warts) (3) Angiogenesis related diseases (like AMD), (4) Fertility preservation following Chemotherapy and Radiothearpy.
The company enjoys the benefit of the results from pre-clinical studies and human clinical trials conducted under two Investigational New Drug applications (INDs) as well as extensive data generated from hundreds of patients treated with AS101 in non-IND trials. These showed the safety, tolerability and efficacy for this molecule. Together with a solid Chemistry, Manufacturing & Controls (CMC) package, the company has set the ground for the launch of advanced and new clinical trials with AS101.
The second generation Tellurium based molecule SAS, following encouraging animal model studies in several indications, is undergoing pre-clinical safety and tolerability GLP studies to support an IND application. Results of the preclinical safety and toxicology as well as full CMC are expected Q2 2015 to support Phase I clinical trials.
